Characteristics and Survival of Patients with the Total Artificial Heart Implanted for Indications Other Than Biventricular Failure

2013 ◽  
Vol 32 (4) ◽  
pp. S231 ◽  
Author(s):  
K.L. Thanavaro ◽  
D.G. Tang ◽  
R.H. Cooke ◽  
A.C. Mankad ◽  
M.L. Hess ◽  
...  
2017 ◽  
Vol 20 (3) ◽  
pp. 266-269 ◽  
Author(s):  
Masashi Kawabori ◽  
Chitaru Kurihara ◽  
Yair Miller ◽  
Kent A. Heck ◽  
Roberta C. Bogaev ◽  
...  

Perfusion ◽  
2016 ◽  
Vol 32 (1) ◽  
pp. 81-83
Author(s):  
Jemma Youdle ◽  
Sarah Penn ◽  
Olaf Maunz ◽  
Andre Simon

We report our first clinical use of the new Protek DuoTM cannula for peripheral veno-venous extra-corporeal life support (ECLS). A 53-year-old male patient underwent implantation of a total artificial heart (TAH) for biventricular failure. However, due to the development of post-operative respiratory dysfunction, the patient required ECLS for six days.


2016 ◽  
Vol 19 (5) ◽  
pp. E229
Author(s):  
Ali Ghodsizad ◽  
Michael M. Koerner ◽  
A El-Banayosy ◽  
Mohamed Zeriouh ◽  
Arjang Ruhparwar ◽  
...  

The SynCardia Total Artificial Heart (TAH) has been used for patients with biventricular failure, who cannot be managed with implantation of a left ventricular (LV) assist device. Following TAH implantation, our patient developed severe hemolysis, which could only be managed successfully by aggressive blood pressure control [Ohashi 2003; Nakata 1998].


2020 ◽  
Vol 61 (6) ◽  
pp. 413-414
Author(s):  
Antigone G. Koliopoulou ◽  
Michael J. Bonios ◽  
Nikolaos A. Diakos ◽  
Stavros G. Drakos

Author(s):  
Jack Copeland ◽  
◽  
Steve Langford ◽  
Joseph Giampietro ◽  
John Arancio ◽  
...  

The SynCardia Total Artificial Heart (TAH, SynCardia Systems, Tucson, AZ) is the only biventricular cardiac replacement approved for bridge to transplantation by the U.S. Food and Drug Administration (FDA) and which carries the European Union CE mark. It has been implanted in about 2000 patients. In experienced centers, 60 to 80 % of implanted patients have been transplanted and over 80 % of those transplanted have lived for over 1 year. The SynCardia TAH has supported potential cardiac recipients with irreversible biventricular failure for up to 6 years, providing physiologic pulsatile flows of 6 to 8 L/min at filling pressures of less than 10 mmHg allowing for optimal perfusion and recovery of organs such as the kidneys and liver. It is a tested device that provides a method for recovering potential transplant candidates who rapidly decompensate from biventricular failure or who have chronic cardiac failure from a variety of etiologies. This article covers the history, mechanical function and monitoring, implantation, patient selection and management, and outpatient use. It also reviews outcome data from the original FDA study as well as contemporary data from experienced centers.


2020 ◽  
Vol 58 (6) ◽  
pp. 1175-1181
Author(s):  
Charles-Henri David ◽  
Philippe Lacoste ◽  
Prakash Nanjaiah ◽  
Philippe Bizouarn ◽  
Thierry Lepoivre ◽  
...  

Abstract OBJECTIVES At our centre, the SynCardia temporary Total Artificial Heart (TAH-t) (SynCardia Systems, LLC, Tucson, AZ, USA) is used to provide long-term support for patients with biventricular failure as a bridge to a transplant. However, a heart transplant (HT) after such support remains challenging. The aim of this retrospective study was to assess the immediate and long-term results following an HT in the cohort of patients who had a TAH-t implant. METHODS A total of 73 patients were implanted with the TAH-t between 1988 and 2019 in our centre. Of these 73 consecutive patients, 50 (68%) received an HT and are included in this retrospective analysis of prospectively collected data. RESULTS In the selected cohort, in-hospital mortality after an HT was 10% (n = 5). The median intensive care unit stay was 33 days (range 5–278). The median hospital stay was 41 days (range 28–650). A partial or total pericardiectomy was performed during the HT procedure in 21 patients (42%) due to a severe pericardial reaction. Long-term survival rates after an HT at 5, 10 and 12 years were 79.1 ± 5.9% (n = 32), 76.5 ± 6.3% (n = 22) and 72.4 ± 7.1% (n = 12), respectively, which was similar to the long-term survival for a primary HT without TAH-t during the same period (n = 686). An HT performed within 3–6 months post-TAH-t implantation appeared to provide the best survival (P = 0.007). Eight (16%) patients required chronic dialysis during the subsequent follow-up period, with 3 patients requiring a kidney transplant. CONCLUSIONS The long-term outcomes with the SynCardia TAH-t as a bridge to transplant in patients with severe biventricular failure are very encouraging. Our review noted that an HT following TAH-t can be technically challenging, especially in the case of a severe pericardial reaction, with potential pitfalls that should be recognized preoperatively.


2018 ◽  
Vol 41 (3) ◽  
pp. 175-177 ◽  
Author(s):  
Prashant Rao ◽  
Jack B Keenan ◽  
Taufiek K Rajab ◽  
Samuel Kim ◽  
Richard Smith ◽  
...  

Introduction: Cardiovascular complications represent the leading cause of morbidity and mortality in patients with Marfan syndrome. Here, we describe a unique case where a total artificial heart was implanted in a young Marfan syndrome woman. Methods: A 22-year-old postpartum African American female with Marfan syndrome developed multiple severe valve dysfunction and biventricular failure that was refractory to medical management. She previously had a Bentall procedure for Type A aortic dissection and repair of a Type B dissection. Results: We implanted a total artificial heart with a good outcome. Conclusion: Total artificial heart is a durable option for severe biventricular failure and multiple valvular dysfunction as a bridge to transplant in a young patient with Marfan syndrome.


Sign in / Sign up

Export Citation Format

Share Document